Middle East & Africa Oncology Based In-vivo Cro Market Size & Outlook
Middle East & Africa oncology based in-vivo cro market, 2018-2030 (US$M)
Related Markets
MEA oncology based in-vivo cro market highlights
- The MEA oncology based in-vivo cro market generated a revenue of USD 25.5 million in 2023.
- The market is expected to grow at a CAGR of 8.4% from 2024 to 2030.
- In terms of segment, solid tumor was the largest revenue generating indication in 2023.
- Solid Tumor is the most lucrative indication segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2024 to 2030.
MEA data book summary
| Market revenue in 2023 | USD 25.5 million |
| Market revenue in 2030 | USD 45.1 million |
| Growth rate | 8.4% (CAGR from 2023 to 2030) |
| Largest segment | Solid tumor |
| Fastest growing segment | Solid Tumor |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Cancer, Solid Tumor |
| Key market players worldwide | Charles River Laboratories International Inc, Icon PLC, Thermo Fisher Scientific Inc, Eurofins Scientific SE, Labcorp Holdings Inc, Wuxi AppTec Co Ltd, Evotec SE, Taconic Biosciences, The Jackson Laboratory |
Other key industry trends
- In terms of revenue, MEA region accounted for 1.9% of the global oncology based in-vivo cro market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 245.2 million by 2030.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oncology Based In-vivo CRO Market Scope
Oncology Based In-vivo CRO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa oncology based in-vivo cro market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oncology based in-vivo cro market will help companies and investors design strategic landscapes.
Solid tumor was the largest segment with a revenue share of 47.45% in 2023. Horizon Databook has segmented the Middle East & Africa oncology based in-vivo cro market based on blood cancer, solid tumor covering the revenue growth of each sub-segment from 2018 to 2030.
Conducting clinical and preclinical trials in MEA offers advantages such as cost advantage, infrastructure, and world-class medical facilities. The only drawback is discrepancies between laws of different regions. Many regions are initiating to adapt to the global standards and collaborating with other global CROs to mark their presence.
For instance, Hassan Labs of Egypt and Saham Group of North Africa joined hands to provide an international level of medical expertise across Africa. To reach out to the clients and to expand in developed countries, MCT participated in the Partnership in Clinical Trial in April 2014. Through this, MCT met sponsors from North America and presented the advantages of conducting research in MEA.
Reasons to subscribe to Middle East & Africa oncology based in-vivo cro market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa oncology based in-vivo cro market databook
-
Our clientele includes a mix of oncology based in-vivo cro market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa oncology based in-vivo cro market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa oncology based in-vivo cro market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
MEA oncology based in-vivo cro market size, by country, 2018-2030 (US$M)
Middle East & Africa Oncology Based In-vivo CRO Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
